UMIN-CTR Clinical Trial

Basic information
Public title	A verification study for the effect of the food containing plant-derived ingredients intake on uric acid level: a randomized, double-blind, placebo-controlled, parallel-group trial
Acronym	A verification study for the effect of the food containing plant-derived ingredients intake on uric acid level
Scientific Title	A verification study for the effect of the food containing plant-derived ingredients intake on uric acid level: a randomized, double-blind, placebo-controlled, parallel-group trial
Scientific Title:Acronym	A verification study for the effect of the food containing plant-derived ingredients intake on uric acid level
Region	Japan

Condition
Condition	Healthy Japanese subjects
Classification by specialty	Not applicable Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To verify the effect of consumption of the test food for 12 weeks on the serum uric acid level
Basic objectives2	Safety,Efficacy
Basic objectives -Others
Trial characteristics_1	Confirmatory
Trial characteristics_2	Pragmatic
Developmental phase	Not applicable

Assessment
Primary outcomes	Serum uric acid level *Measure the level at screening (before consumption) and 4, 8, and 12 weeks after consumption and calculate the amount of change.
Key secondary outcomes	1. Urinary uric acid level 2. Urinary creatinine level 3. Urinary uric acid/urinary creatinine ratio 4. Subjective symptoms (the Likert scale) *1-4Measure the values and levels at screening (before consumption) and 4, 8, and 12 weeks after consumption and calculate the amount of change.

Base
Study type	Interventional

Study design
Basic design	Parallel
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification	YES
Dynamic allocation	NO
Institution consideration	Institution is not considered as adjustment factor.
Blocking	YES
Concealment	Central registration

Intervention
No. of arms	2
Purpose of intervention	Treatment
Type of intervention	Food
Interventions/Control_1	Duration: 12 weeks Test food: Tablet containing plant-derived ingredients Administration: Take 4 tablets, once per day at any time during the day.
Interventions/Control_2	Duration: 12 weeks Test food: Placebo tablets Administration: Take 4 tablets, once per day at any time during the day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	75 years-old >
Gender	Male and Female
Key inclusion criteria	1. Healthy subjects 2. Japanese adult subjects 3. Subjects who are determined as eligible to participate in the study by the physician 4. Subjects who are between >=6.1 mg/dL and <7.0 mg/dL, or >=7.0 mg/dL and <=7.9 mg/dL in serum uric acid level
Key exclusion criteria	1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, hyperuricemia, obesity (based on the standard definition by the Japan Society for the Study of Obesity), or any other chronic diseases 4. Subjects who have had symptoms of gout 5. Subjects who work late-night shift or are irregular of their life-styles 6. Subjects who excessively exercise 7. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional foods/beverages in daily 8. Subjects who are currently taking medications (including herbal medicines) and supplement. Particularly, diosmin, anticoagulant drugs, antiplatelet drugs, antihypertensive drugs (celiprolol hydrochloride, diltiazem hydrochloride, and etc.), diazepam, central nervous system depressant, and vasodilator drugs (verapamil) 9. Subjects who are an allergic reaction to medications and/or products that contain the study ingredients, particularly citrus. 10. Subjects who are pregnant, lactation, or planning to become pregnant 11. Subjects who have been enrolled in another clinical study within the last three months prior to signing informed consent for the current study or plan to enroll in anther clinical study during study period 12. Subjects who are ineligibility to participate in the study based on the evaluation of the principal physician
Target sample size	160

Research contact person
Name of lead principal investigator	1st name Kazuo Middle name Last name YAMAMOTO
Organization	ORTHOMEDICO Inc.
Division name	CEO
Zip code	112-0002
Address	2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL	03-3818-0610
Email	kazu@orthomedico.jp

Public contact
Name of contact person	1st name Naoko Middle name Last name SUZUKI
Organization	ORTHOMEDICO Inc.
Division name	R&D Department
Zip code	112-0002
Address	2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL	03-3818-0610
Homepage URL
Email	nao@orthomedico.jp

Sponsor
Institute	ORTHOMEDICO Inc.
Institute
Department

Funding Source
Organization	Sapporo Holdings Ltd.
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor	Medical Corporation Seishinkai, Takara Clinic
Name of secondary funder(s)

IRB Contact (For public release)
Organization	The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address	9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
Tel	03-5793-3623
Email	info@takara-clinic.com

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions	医療法人社団盛心会 タカラクリニック (東京都) Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

Other administrative information
Date of disclosure of the study information	2019 Year 09 Month 30 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled	166
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Completed
Date of protocol fixation	2018 Year 12 Month 11 Day
Date of IRB	2018 Year 12 Month 11 Day
Anticipated trial start date	2018 Year 12 Month 19 Day
Last follow-up date	2019 Year 09 Month 14 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date	2018 Year 12 Month 18 Day
Last modified on	2020 Year 03 Month 24 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040200